Finance

Lists
EBS:NYSE
Emergent Biosolutions Inc
6,90 US$
-0,14%
(-0,0100) 1D
14 ოქტ, 11:06:26 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for EBS...
Open
6,87 US$
High
7,02 US$
Low
6,81 US$
Mkt. cap
353,79 მლნ.
Avg. vol.
1,14 მლნ.
Volume
173,56 ათ.
52-wk high
14,06 US$
52-wk low
4,36 US$
EPS
-3,51 US$
Beta
2,28
Shares outstanding
51,27 მლნ.
No. of employees
900
Open
6,87 US$
High
7,02 US$
Low
6,81 US$
Mkt. cap
353,79 მლნ.
Avg. vol.
1,14 მლნ.
Volume
173,56 ათ.
52-wk high
14,06 US$
52-wk low
4,36 US$
EPS
-3,51 US$
Beta
2,28
Shares outstanding
51,27 მლნ.
No. of employees
900
News stories
From web sources and news partners
Profile
Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes. Among the company's products are the controversial BioThrax, the only anthrax vaccine licensed by the U.S. Food and Drug Administration and Narcan for the emergency treatment of opioid overdose. The company also manufactures pharmaceuticals for infectious diseases like cholera and typhoid. During the COVID-19 pandemic, Emergent BioSolutions also produced Johnson & Johnson/Janssen and Oxford–AstraZeneca vaccines at one of its plants; however, this was marked by contamination and other production issues, and millions of doses of vaccine had to be discarded. Wikipedia
About Emergent Biosolutions Inc
CEORobert G. Kramer Sr. | ჯოზეფ სი პაპა
Employees900
Founded5 სექ. 1998
Headquartersროკვილი, მერილენდი, ამერიკის შეერთებული შტატები
Sector-
Analyst ratings
Based on 2 analysts giving stock ratings to EBS in the past 3 months
Hold
Buy
1
Hold
0
Sell
1
12-month forecast
Based on 2 Wall Street analysts offering 12 month price targets for EBS in the last 3 months.
Highest
Current 6,90 US$
10,00 US$ (+44,93%)
Average
10,00 US$ (+44,93%)
Lowest
10,00 US$ (+44,93%)
Analyst
Recommendation
Action
Price target
Projected
Date
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
10,00 US$
+44,9%
09/09/2026
Jessica Fye
J.P. Morgan
Sell
Initiated
-
-
08/21/2026
Last report
5 აგვ. 2026
Fiscal period
Q2 2026
0,60 US$ / 0,11 US$
+445,45%beat
Revenue / Est. (USD)
234,30 მლნ. / 177,50 მლნ.
+32,00%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
231,10 მლნ.
148,70 მლნ.
156,10 მლნ.
234,30 მლნ.
Cost of goods sold
99,00 მლნ.
94,00 მლნ.
82,40 მლნ.
106,10 მლნ.
Cost of revenue
99,00 მლნ.
94,00 მლნ.
82,40 მლნ.
106,10 მლნ.
Research and development expenses
200,00 ათ.
-600,00 ათ.
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
28,30 მლნ.
61,60 მლნ.
46,60 მლნ.
44,60 მლნ.
Operating expense
44,80 მლნ.
77,30 მლნ.
63,10 მლნ.
61,80 მლნ.
Total operating expenses
143,80 მლნ.
171,30 მლნ.
145,50 მლნ.
167,90 მლნ.
Operating income
87,30 მლნ.
-22,60 მლნ.
10,60 მლნ.
66,40 მლნ.
Other non operating income
-3,70 მლნ.
-8,10 მლნ.
13,90 მლნ.
-
EBT including unusual items
57,60 მლნ.
-50,70 მლნ.
13,40 მლნ.
-166,30 მლნ.
EBT excluding unusual items
68,40 მლნ.
-45,40 მლნ.
13,50 მლნ.
56,40 მლნ.
Income tax expense
6,40 მლნ.
3,90 მლნ.
6,60 მლნ.
13,90 მლნ.
Effective tax rate
11,11%
-7,69%
49,25%
-8,36%
Other operating expenses
-
-
-
-
Net income
51,20 მლნ.
-54,60 მლნ.
6,80 მლნ.
-180,20 მლნ.
Net profit margin
22,15%
-36,72%
4,36%
-76,91%
Earnings per share
1,06
-0,43
0,21
0,60
Interest and investment income
-
-
-
-
Interest expense
-15,20 მლნ.
-14,70 მლნ.
-11,00 მლნ.
-10,00 მლნ.
Net interest expenses
-15,20 მლნ.
-14,70 მლნ.
-11,00 მლნ.
-10,00 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
110,30 მლნ.
2,40 მლნ.
33,50 მლნ.
89,90 მლნ.
Gain or loss from assets sale
2,20 მლნ.
-11,20 მლნ.
800,00 ათ.
11,90 მლნ.
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google აპები